Keywords
Defined daily dose
COVID-19
Pharmacoepidemiology
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Identify and quantify the consumption of antimicrobials in a highly complex public hospital in the first wave of COVID-19. Methods: Descriptive, cross-sectional, and retrospective study carried out at a high-complexity hospital. Two periods were evaluated: pre-pandemic and the first wave of the pandemic. Antimicrobial consumption was expressed in Defined Daily Dose (DDD) per 1000 patients/day. The World Health Organization ATC/DDD classification was used. Results: During the pre-pandemic period, the average monthly hospital admission rate was 283 admissions; in contrast, in the first wave of COVID-19, this average reduced to 138 admissions. In the first wave of COVID-19, the most used antimicrobial was ceftriaxone, followed by piperacillin + tazobactam, cefepime, meropenem, and vancomycin. In the Intensive Care Unit (ICU), there was a considerable increase in the consumption of fourth and third generation cephalosporins, carbapenems, and broad-spectrum penicillins. Conclusion: Our findings showed a general increase in some antimicrobials, which could aggravate antimicrobial resistance. The impact of the pandemic on this issue is still unknown, raising concerns about the consequences for future generations.
References
AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA (ANVISA). Gerência Geral de Tecnologia em Serviços de Saúde. Gerência de Vigilância e Monitoramento em Serviços de Saúde. Diretriz Nacional para Elaboração de Programa de Gerenciamento do Uso de Antimicrobianos em Serviços de Saúde, 2017; 75.
AMARSY R, et al. Surging bloodstream infections and antimicrobial resistance during the first wave of COVID–19: a study in a large multihospital institution in the Paris region. International Journal of Infectious Diseases, 2022; 114: 90-96.
BACCOLINI V, et al. The impact of the COVID-19 pandemic on healthcare-associated infections in intensive care unit patients: a retrospective cohort study. Antimicrobial Resistance & Infection Control, 2021; 10(1): 87.
BADIN RC, et al. Clinical and pharmacological factors associated with mortality in patients with COVID-19 in a high complexity hospital in Manaus: A retrospective study. Plos one, 2023; 18(2): e0280891.
BAGUMA S, et al. Factors associated with mortality among the COVID-19 patients treated at Gulu Regional Referral Hospital: A retrospective study. Frontiers in Public Health, 2022; 10: 841906.
BALKHY HH, et al. Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study. Antimicrobial Resistance and Infection Control, 2018; 7(1): 1-9.
BOUCHER HW e COREY GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2008; 46(5): S344–S349.
BORK JT, et al. Change in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019. Infection Control & Hospital Epidemiology, 2021; 42(9): 1115-1117.
BRASIL. Ministério da Saúde. Boletins epidemiológicos. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos. Acesso em 05 de Junho de 2023.
BUSS LF, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science, 2021; 371(6526): 288-292.
CÂNDIDO SS, et al. Retrato do uso de carbapenêmicos em um hospital pertencente ao sistema único de saúde. Research, Society and Development, 2022; 11(9): e16811931647.
CARS O, et al. The global need for effective antibiotics-moving towards concerted action. Drug resistance updates, 2011; 14(2): 68-69.
CASTRO A, et al. Increase of Antimicrobial Consumption in a Tertiary Care Hospital during the First Phase of the COVID-19 Pandemic. Antibiotics, 2021; 10(7): 778.
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. US Department of Health and Human Services, CDC, 2013; 114.
CHANG CY e SCHIANO TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther., 2007; 25(10): 1135-1151.
CISNEROS JM, et al. Uso prudente de antibióticos y propuestas de mejora desde la medicina hospitalaria. Enfermedades infecciosas y microbiologia clinica, 2010; 28: 28-31.
DADGOSTAR P. Antimicrobial resistance: implications and costs. Infection and drug resistance, 2019; 3903-3910.
DAHER AA, et al. Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit. Scientific Reports, 2021; 11(1): 1-7.
FERRER-OLIVEIRAS R, et al. Immunological and physiopathological approach of COVID-19 in pregnancy. Archives of gynecology and obstetrics, 2021; 304(1): 39-57.
DOS SANTOS P, et al. Análise farmacoeconômica dos antimicrobianos na unidade de terapia intensiva em um hospital terciário. Research, Society and Development, 2020; 9(5): e104953179.
GOOSSENS H, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet, 2005; 365(9459): 579-587.
GRAU S, et al. Antimicrobial consumption among 66 acute care hospitals in Catalonia: impact of the COVID-19 pandemic. Antibiotics, 2021; 10: 943.
HAMIDI AA e YILMAZ Ş. Antibiotic consumption in the hospital during COVID-19 pandemic and distribution of bacterial agents and antimicrobial resistance: A single-center study. Journal of Surgery and Medicine, 2021; 5(2): 124-127.
LANGFORD B, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical microbiology and infection, 2020; 26(12): 1622-1629.
LANSBURY L, et al. Co-infections in people with COVID-19: A systematic review and meta-analysis, 2020; 81(2): 266-275.
LEEKHA S, et al. General principles of antimicrobial therapy. In: Mayo clinic proceedings. Elsevier, 2011; 156-167.
LIEW Y, et al. Antimicrobial stewardship programme: a vital resource for hospitals during the global coronavirus disease 2019 (COVID-19) outbreak. International journal of antimicrobial agents, 2020; 56(5): 106145.
LODE H. Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. The American journal of medicine, 2010; 123(4): S26-S38.
LOUREIRO RJ, et al. O uso de antibióticos e as resistências bacterianas: breves notas sobre a sua evolução. Revista Portuguesa de saúde pública, 2016; 34(1): 77-84.
MAJUMDER MAA, et al. Antimicrobial stewardship: Fighting antimicrobial resistance and protecting global public health. Infection and drug resistance, 2020; 4713-4738.
MARINHO MG, et al. Estudo de consumo de antimicrobianos do Centro de Terapia Intensiva de um hospital Universitário da Região Norte. Research, Society and Development, 2022; 11(5): e0611527592.
MONNET DL e HARBARTH S. Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?. Eurosurveillance, 2020; 25(45): 2001886.
MURRAY CJ, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 2022; 399(10325): 629-655.
O’NEIL J. Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations 2014, 2014; 20.
RAWSON TM, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. Journal of antimicrobial chemotherapy, 2020; 75(7): 1681-1684.
SAINI V, et al. Paradigm shift in antimicrobial resistance pattern of bacterial isolates during the COVID-19 pandemic. Antibiotics, 2021; 10(8): 954.
SALES I, et al. Análise comportamental da COVID-19 no brasil: Análise de dados da mobilidade, contaminação e medidas restritivas no país. Acta Scientia, 2020; 2(1): 73-85.
SILVA AR, et al. Increased use of antibiotics in the intensive care unit during coronavirus disease (COVID-19) pandemic in a brazilian hospital. Frontiers in pharmacology, 2021; 12: 778386.
UL MUSTAFA Z, et al. Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Compr Clin Med., 2021; 3(8): 1691-1695.
VARELA MF, et al. Bacterial resistance to antimicrobial agents. Antibiotics, 2021; 10(5): 593.
VELLANO PO e DE PAIVA MJM. O uso de antimicrobiano na COVID-19 e as infecções: o que sabemos. Research, Society and Development, 2020; 9(9): e841997245.